Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $29.00.

KYTX has been the subject of a number of research reports. Benchmark reiterated a “buy” rating on shares of Kyverna Therapeutics in a research report on Friday, September 25th. William Blair raised Kyverna Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Needham & Company LLC set a $25.00 price target on Kyverna Therapeutics in a report on Friday, September 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Monday, September 21st. Finally, HC Wainwright reiterated a “buy” rating on shares of Kyverna Therapeutics in a report on Thursday, October 22nd.

Kyverna Therapeutics Price Performance

NASDAQ KYTX opened at $5.67 on Wednesday. Kyverna Therapeutics has a 12-month low of $5.16 and a 12-month high of $13.67. The company has a quick ratio of 9.06, a current ratio of 9.06 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $350.63 million, a PE ratio of -1.93 and a beta of 2.12. The company has a 50 day moving average price of $6.91 and a two-hundred day moving average price of $8.09.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its earnings results on Tuesday, August 11th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.05. As a group, equities analysts predict that Kyverna Therapeutics will post -2.70 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Legal & General Group Plc acquired a new stake in shares of Kyverna Therapeutics in the second quarter worth $36,000. North Star Investment Management Corp. bought a new stake in shares of Kyverna Therapeutics during the third quarter worth approximately $68,000. Oppenheimer & Co. Inc. bought a new stake in shares of Kyverna Therapeutics during the 3rd quarter worth approximately $78,000. Baldwin Wealth Partners LLC MA acquired a new position in shares of Kyverna Therapeutics during the third quarter worth $95,000. Finally, State of Wyoming acquired a new stake in shares of Kyverna Therapeutics in the second quarter valued at about $97,000. 18.08% of the stock is owned by institutional investors and hedge funds.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical-stage biotechnology company developing engineered T-cell therapies for patients with severe autoimmune diseases. The company’s approach is designed to selectively eliminate disease-causing B cells, which play a central role in many autoimmune disorders, with the goal of achieving deep and durable disease remission.

Kyverna’s lead investigational product, KYV-101, is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The treatment is being evaluated in clinical studies for conditions including lupus nephritis, systemic sclerosis, multiple sclerosis and other serious autoimmune diseases.